We are live on ! Find out more

VistaGen Therapeutics

VTGN

Market cap $11.2M

0.2529 USD

-0.0041

1.6%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

0.2602

+0.0073

2.89%

1 day

-1.6%

5 days

5.64%

1 month

8.63%

3 months

-60.07%

6 months

-57.59%

Year to date

-62.75%

1 year

-92.17%

5 years

-99.71%

10 years

-99.72%

About: Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Employees: 41

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 88.9%

Negative 11.1%

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of its exploratory Phase 2 repeat dose study evaluating fasedienol nasal spray in adult subjects with social anxiety disorder.

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Douglas J. Williamson to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study population.

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder. PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase.

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2026, and provided a corporate update. "We made meaningful progress in fiscal 2026, advancing three significant late-stage programs in our novel pherine pipeline.

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company's clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory.

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Vistagen Therapeutics caused the company to misrepresent or fail to disclose the risk of failure inherent in public speaking challenge-based Social Anxiety Disorder clinical trials.

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healthcare Conference.

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

See News Rankings

Price charts implemented using Lightweight Charts™